CareMax (CMAX) Gets a Hold From Truist Financial
CareMax Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG), CareMax (CMAX) and NovoCure (NVCR)
UBS Adjusts CareMax Price Target to $7 From $30, Maintains Neutral Rating
Truist Financial Keeps Their Hold Rating on CareMax (CMAX)
Buy Rating Reaffirmed for CareMax Amid Strategic Shift Toward Free Cash Flow and Long-term Growth
UBS Downgrades CareMax to Neutral From Buy, Adjusts Price Target to $1 From $5
UBS Downgrades CareMax to Neutral, Lowers Price Target to $1
CareMax Analyst Ratings
CareMax (CMAX) Gets a Hold From Truist Financial
CareMax's Mixed Financial Performance and Outlook: A Comprehensive Analysis for a Hold Rating
Piper Sandler Downgrades CareMax to Neutral, Announces $2 Price Target
CareMax Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: CareMax (CMAX), Bausch + Lomb Corporation (BLCO) and Arcus Biosciences (RCUS)
Truist Financial Reaffirms Their Hold Rating on CareMax (CMAX)
UBS Adjusts CareMax Price Target to $5 From $6, Maintains Buy Rating
CareMax Downgraded to Market Perform at Cowen on Challenging Full-risk, EBITDA Projections
TD Cowen Downgrades CareMax to Market Perform From Outperform, Adjusts Price Target to $4 From $7
UBS Adjusts CareMax's Price Target to $6 From $10, Maintains Buy Rating
UBS Maintains Buy on CareMax, Lowers Price Target to $6